pg Scientific Papers

Some of the key scientific papers that have been recently published by members of our Advisory Council on their Rhabdo research

Keller Labs ? Rota Labs ? Hawkins Labs ? Fulda Labs ? Fanzani Labs

Keller Laboratory

Proof-of-Concept Rare Cancers in Drug Development: The Case for Rhabdomyosarcoma  
Elizabeth Sokolowski, Claire B. Turina, Ken Kikuchi, David M. Langenau, Charles KellerOncogene, epub 2013 May 13 [PMID 23665679]

IL-4 receptor blockade abrogates satellite cell - rhabdomyosarcoma fusion and prevents tumor establishment
Guangheng Li, Ken Kikuchi, Charles Keller.   Stem Cells  2013 Nov;31(11):2304-12 [PMID 23897781]

Dynamic and Nuclear expression of Pdgfrα and Igf1r in Alveolar Rhabdomyosarcoma 
M. Imran Aslam, Simone Hettmer, Dorian LaTocha, Anuradha Soundararajan, Elaine T. Huang, Martin W. Goros, Joel E. Michalek, Shuyu Wang, Atiya Mansoor, Brian J. Druker, Amy J. Wagers, Jeffrey W. Tyner, Charles Keller.  Molecular Cancer Research, 2013 Nov;11(11):1303-13 [PMID 23928059]

Overcoming Autopsy Barriers in Pediatric Cancer Research
Jennifer L. Alabran, Jody E. Hooper, Melissa Hill, Sandra E. Smith, Kimberlee K. Spady, Lara E. Davis, Lauren S. Peterson, Suman Malempati, Christopher W. Ryan, Rae Acosta, Sheri L. Spunt, Charles Keller.  Pediatric Blood & Cancer, 2013 Feb;60(2):204-9 [PMID 23015377, PMC3522778]

Protein Kinase C iota as a Therapeutic Target in Alveolar Rhabdomyosarcoma
Ken Kikuchi, Anuradha Soundararajan, Lee Ann Zarzabal, Capella R. Weems, Laura D. Nelon, Sheila T. Hampton, Joel A. Michalek, Brian P. Rubin, Alan P. Fields,Charles Keller. Oncogene, 2013 Jan 17;32(3):286-95 [PMID 22349825PMC3360112

MDM2 Amplification and PI3KCA mutation in a Case of Sclerosing Rhabdomyosarcoma
Ken Kikuchi, George R. Wettach, Christopher W. Ryan, Arthur Hung, Mingkui Chen, Jody E. Hooper, Carol Beadling, Andrea Warrick, Christopher L. Corless, Susan B. Olson, Jonathan Hart, Peter K. Vogt, Charles Keller*, Atiya Mansoor* (*co-corresponding). Sarcoma, 2013:520858. doi: 10.1155/2013/520858. Epub 2013 May 20 [PMID 23766666PMC3673319]

Mechanisms of Impaired Differentiation in Rhabdomyosarcoma
Charles Keller and Denis C. Guttridge.  FEBS Letters, 2013 Sep;280(17):4323-34 [PMID 23822136]

Rota Laboratory

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx)
R Ciarapica, M De Salvo1, E Carcarino, G Bracaglia, L Adesso, PP Leoncini, A Dall’Agnese, ZS Walters, F Verginelli, L De Sio, R Boldrini, A Inserra, G Bisogno, A Rosolen, R Alaggio, A Ferrari, P Collini, M Locatelli, S Stifani, I Screpanti, S Rutella, Q Yu, VE Marquez, J Shipley, S Valente, A Mai, L Miele, PL Puri, F Locatelli, D Palacios and R Rota Oncogene (2013)
View PDF ? View Supplementary Data ? View Supplementary Figures

Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo
L Raimondi, R Ciarapica, M De Salvo, F Verginelli, M Gueguen, C Martini, L De Sio, G Cortese, M Locatelli, TP Dang,
N Carlesso, L Miele, S Stifani, I Limon, F Locatelli, and R Rota* Cell Death and Differentiation (2012)
View PDF

Notch signaling in pediatric soft tissue sarcomas
Rossella Rota, Roberta Ciarapica, Lucio Miele and Franco Locatelli BMC Medicine 2012
View PDF

Hawkins Laboratory

PAX-FOXO1 Fusion Status Drives Unfavorable Outcome for Children With Rhabdomyosarcoma: A Children’s Oncology Group Report
Stephen X. Skapek, MD, James Anderson, PhD, Frederic G. Barr, MD,PhD, JuliaA. Bridge, MD, JulieM.Gastier-Foster, PhD,
David M. Parham, MD, Erin R. Rudzinski, MD, Timothy Triche, MD, PhD, and Douglas S. Hawkins, MD Pediatr Blook Cancer 2013
View PDF

REVIEW - Children’s Oncology Group’s 2013 Blueprint for Research: Soft Tissue Sarcomas
Douglas S. Hawkins, MD, Sheri L. Spunt, MD, and Stephen X. Skapek, MD on behalf of the COG Soft Tissue Sarcoma Committee Pediatr Blook Cancer 2013
View PDF

Histologic and Clinical Characteristics Can Guide Staging Evaluations for Children and Adolescents With Rhabdomyosarcoma: A Report From the Children’s Oncology Group Soft Tissue Sarcoma Committee
Aaron R. Weiss, Elizabeth R. Lyden, James R. Anderson, Douglas S. Hawkins, Sheri L. Spunt, David O. Walterhouse, Suzanne L. Wolden, David M. Parham, David A. Rodeberg, Simon C. Kao, and Richard B. Womer Journal of Clinical Oncology, Sept 10, 2013
View PDF

Fulda Lab

Pan-mTOR inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by downregulating Mcl-1.
Preuss E, Hugle M, Reimann R, Schlecht M, Fulda S. J Biol Chem [Epub ahead of print] 2013 Oct 16 PMID 24133218

Fanzani Lab

Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
Fiorella Faggi, Stefania Mitola, Guglielmo Sorci, Francesca Riuzzi,
Rosario Donato, Silvia Codenotti, Pietro Luigi Poliani, Manuela Cominelli,
Raffaella Vescovi, Stefania Rossi, Stefano Calza, Marina Colombi, Fabio
Penna, Paola Costelli, Ilaria Perini, Maurilio Sampaolesi, Eugenio Monti,
Alessandro Fanzani. PlosOne 2013, in Press (will be made availabe as soon as published).

Muscular dystrophies share pathogenetic mechanisms with muscle sarcomas
Alessandro Fanzani, Eugenio Monti, Rosario Donato, and Guglielmo Sorci Trends in Molecular Medicine September 2013
View PDF

Rhabdomyosarcomas: an overview on the experimental animal models
Alessandra Zanola, Stefania Rossi, Fiorella Faggi, Eugenio Monti, Alessandro Fanzani J. Cell. Mol. Med. Vol 16, No 7, 2012
View PDF